Shanghai ChemPartner CEO Michael Hui On Finding A Niche In China Amidst Increasing Foreign Competition: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Shanghai ChemPartner was set up in 2003 at Shanghai's Zhangjiang Hi-Tech Park, and today it is one of the leading R&D outsourcing providers in China. PharmAsia News recently visited company headquarters to meet Michael Hui, CEO of ChemPartner - as well as sister company ChemExplorer, and their holding company ShangPharma - to discuss the company's recent deal with private equity investment firm TPG, as well as handling increased competition from foreign firms moving into China.
You may also be interested in...
Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.
Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.
Eli Lilly's China R&D Head Tony Zhang On Looking At The Universe Of Possibilities In China: An Interview With PharmAsia News
Eli Lilly was the first to coin the term FIPNET, which brings the focus of becoming a fully integrated pharmaceutical network on partnerships rather than doing it all as a fully integrated pharmaceutical company, or FIPCO. Eli Lilly's Head of China R&D Tony Zhang sat down with PharmAsia News along the sidelines of the recent Shanghai R&D Summit to discuss Lilly's approach to R&D in China. Much of doing R&D in China is about building up a local ecosystem for innovation and, according to Zhang, it is about being a "sower and a grower," rather than just a "seeker and a picker."